The combination of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab (DA-EPOCH-R) is used for treatment of non-Hodgkin lymphoma. Febrile neutropenia (FN) is a common complication of treatment with myelo-suppressive chemotherapy, therefore, preventing FN is important for successful treatment. The authors compared the efficacy of pegfilgrastim with that of filgrastim in patients receiving DA-EPOCH-R and showed that pegfilgrastim seems to be better than filgrastim for the primary prophylaxis, maintaining chemotherapy dosage, and reducing hospital duration.
What Is Qualitative Research?
Released: June 01, 2017 | Volume 137 Issue 6 Pages 653-658
Home Medical Care for Heart Failure Patients: Pharmaceutical Education Program of Chiba University
Released: June 01, 2018 | Volume 138 Issue 6 Pages 783-785
Differences of Pain Anesthetic Effect Expression on Using Lidocaine Tape in Hemodialysis Patients
Released: November 01, 2007 | Volume 127 Issue 11 Pages 1797-1799
An Approach for Safe Medication Assistance in Nursing Homes: A Workshop to Identify Problems of and Plan Measures for Care Workers
Released: June 01, 2016 | Volume 136 Issue 6 Pages 913-923
Hyerim Park, Akiko Miki, Hiroki Satoh, Hideyuki Maki, Kohei Asai, Yukari Konishi, Yasufumi Sawada
Activation of Natural Killer T Cells by NK-4, a Criptocyanine Dye
Released: November 01, 2011 | Volume 131 Issue 11 Pages 1667-1674
Toshio KUNIKATA, Keizo KOHNO, Shimpei USHIO, Shigeharu FUKUDA